title: A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis.
abstract: BACKGROUND
  Sulfasalazine is accepted therapy for active ulcerative colitis, but side-effects and intolerance are common. Balsalazide is an azo-bonded pro-drug which also releases 5-aminosalicylic acid into the colon, but uses an inert carrier molecule.
  
  
  OBJECTIVE
  To compare the safety and efficacy of sul- fasalazine, 3 g, with balsalazide, 6.75 g, in the initial daily treatment of mild to moderate ulcerative colitis.
  
  
  METHODS
  A randomized, multicentre, double-blind, parallel group study was performed, with a treatment duration of 8 weeks. Patients on previous maintenance treatment were excluded. The trial medication was the sole treatment for the colitis. Efficacy was assessed by patient diaries, symptom assessment, sigmoidoscopic appearance and histology.
  
  
  RESULTS
  Fifty patients were recruited: 26 allocated to the balsalazide group and 24 to the sulfasalazine group. More patients withdrew due to adverse events in the sulfasalazine group (nine patients vs. one patient in the balsalazide group, P=0.004). Improvement occurred in both groups, with a tendency to a faster response with balsalazide. Of the patients taking balsalazide, 61% achieved clinical and sigmoidoscopic remission.
  
  
  CONCLUSIONS
  Balsalazide, 6.75 g, is effective as the sole treatment for patients with mild to moderately active ulcerative colitis, with significantly fewer withdrawals due to side-effects than in a similar group of patients taking sulfasalazine, 3 g.
authors.affiliation: Gastroenterology Unit, Royal Hallamshire Hospital, Sheffield, UK. j.c.mansfield@ncl.ac.uk
authors.forename: J C
authors.initials: JC
authors.lastname: Mansfield
authors.forename: M H
authors.initials: MH
authors.lastname: Giaffer
authors.forename: P A
authors.initials: PA
authors.lastname: Cann
authors.forename: D
authors.initials: D
authors.lastname: McKenna
authors.forename: P C
authors.initials: PC
authors.lastname: Thornton
authors.forename: C D
authors.initials: CD
authors.lastname: Holdsworth
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000636:Aminosalicylic Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000473:pathology; D004311:Double-Blind Method; D005260:Female; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D006801:Humans; D008297:Male; D019804:Mesalamine; D008875:Middle Aged; D010659:Phenylhydrazines; D012720:Severity of Illness Index; D012812:Sigmoidoscopy; D012460:Sulfasalazine / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D016896:Treatment Outcome
chemical_list: D000636:Aminosalicylic Acids; D000897:Anti-Ulcer Agents; D005765:Gastrointestinal Agents; D010659:Phenylhydrazines; D012460:Sulfasalazine; D019804:Mesalamine; C038637:balsalazide